Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2022 Q2- Text added to 2022 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
accretion, adalimumab, aforementioned, argued, ASC, ATM, begun, benchmark, bifurcation, biosimilar, category, Codification, composition, creation, de, deposit, Detachable, donut, embedded, EquitySM, HHS, hole, identification, inflation, IRA, issuer, lifted, NDA, ninety, outpace, paper, placement, reconciliation, regularly, Subtopic, uncollectability, unrealized, ustekinumab, Wainwright, worse
Removed:
actively, assuming, complying, daily, main, representing, transact
Valuein 2022 Q2 filing- Value in 2022 Q3 filing
Original filings
Filing view